





2011中美医药产业峰会"纪念册

Album of Sino-U.S. Pharmaceutical Industry Summit 2011

主办:中国国际商会 中国医药工业科研开发促进会 美国商会 美国药品研究与制造商协会 Hosts: China Chamber of International Commerce (CCOIC)

China Pharmaceutical Industry Research and Development Association (SINO-PhIRDA)

U.S. Chamber of Commerce

Pharmaceutical Research and Manufacturers of America (PhRMA)

2011年10月18-19日, 北京 October 18-19, Beijing



制作: 中国医药工业科研开发促进会



中国全国人大常委会副委员长、中国工程院院士桑国卫出席峰会并致辞。 Address by Sang Guowei, Vice Chairman of the Standing Committee of National People's Congress, Academician of Chinese Academy of Engineering

在"2011中美医药产业峰会"上的致辞

全国人大常委会副委员长

桑国卫院士

2011年10月18日

非常高兴能与各位医药界同仁就知识产权保护与医药产业创新发展 主题共同进行研究和探讨。众所周知,医药产业是一个重要的民生产业 ,医药产业的健康可持续发展关系到国民的生命健康和社会和谐、稳定 与繁荣,加速医药科技发展,加快培育医药产业,已经成为全球的共识 。而创新能力是促进医药产业健康可持续发展的核心竞争力。在政府支 持和中国医药产业界的不懈努力下,中国医药产业正在稳步发展。

目前,中国医药产业界面临的机遇和挑战都是前所未有的,加强医药知识产权保护,既是保护创新者合法权益的必然要求,也是落实国家支持新药创制和鼓励创新政策的重要法律措施。医药知识产权保护对整个国家的战略安全、社会经济和谐发展、医药产业健康成长和全民健康水平的普遍提升,都有着至关重要的作用。

中国政府高度重视知识产权保护工作,在中国政府发布的《国家知识产权战略纲要》中,明确提出国家知识产权战略目标,即到2020年,把我国建设成为知识产权创造、运用、保护和管理水平较高的国家。我们有理由相信,中国的知识产权保护制度将越来越完善。

有数据显示,自我国1992年修订《专利法》,并将药品纳入专利保护范围以来,我国制药企业已经获得了大量药品专利授权。1993年-2011年,我国共授权化学药品专利23996件,其中国内专利授权16643件,占总量的69.3%。特别是实施"十一五"重大新药创制科技重大专项以来,我国研制的具有自主知识产权的药品已经逐渐开始角逐国际市场。因此加强药品知识产权的保护,已经成为中国制药企业的内在需求。

近年来,中国在生物医药行业的知识产权保护方面,取得了重大进展,中国政府执法部门和相关行政部门采取了联合行动,以保护药品专利,并维护创新医药产品完全的权利。我认为中美生物医药企业的国际合作,以及促进改善医药产品的知识产权保护,对于双方都具有不可估量的重要性。

中国药促会和美国PhRMA自2009年以来,已经成功举办了两届医药产业峰会,并取得了积极成果。我衷心希望本届峰会能够充分发挥两个医药专业团体在中美医药产业之间的桥梁纽带作用,为促进全球医药产业的知识产权保护与创新发展、提高人类的健康保障水平做出贡献。

预祝本次峰会取得圆满成功,谢谢大家!

Address on 2011 Sino-U.S. Pharmaceutical Industry Summit Sang Guowei, Vice Chairman of NPC Standing Committee

I am very pleased to have this great opportunity to discuss on the topic of ''Intellectual Property Rights Protection & Pharmaceutical Industry Innovation and Development'' with all colleagues in pharmaceutical industry. As we all know, pharmaceutical industry is an important livelihood industry. The healthy and sustainable development of pharmaceutical industry is closely related to people's life and health, as well as the harmony, stability and prosperity of the society. Accelerating the development of medical science and technology, promoting the development of pharmaceutical industry have become a global consensus. Moreover, the innovation ability is the core competitiveness to facilitate the healthy and sustainable development of pharmaceutical industry. China's pharmaceutical industry has been developing rapidly under the unremitting efforts and the support from government.

At present, pharmaceutical industry in China is facing unprecedented opportunities and challenges. It is not only a necessary requirement to protect the legal rights of innovators, but also important legal measures in implementation of national policies on drug innovation to strengthen the protection of the pharmaceutical intellectual property rights. Pharmaceutical intellectual property rights protection is playing a crucial role in the entire country's strategic security, social harmony and economic development, as well as the healthy growth of pharmaceutical industry and the improvement of people's healthcare level.

Chinese government attaches great importance to the work on intellectual property protection. As stated in <The Outlines of National Intellectual Property Strategy>, ''By 2020, China should be constructed into a country with high level of intellectual property rights creation, utilization, protection and management. We have reasons to believe that China's intellectual property right protection system will be gradually improved.

Statistics show that since China revised "Patent Law" in 1992 and included drugs into the scope of patent protection, China's pharmaceutical industry has received a large number of pharmaceutical patents. From 1993 to 2011, China has authorized a total number of 23,996 chemical patents, 16,643 or 69.3% of which are domestic. Especially, since the implementation of the National Key Project on "Innovation and Development of Major New Drug", drugs with independent intellectual property rights invented by China have gradually started to compete on the international market. Therefore, to enhance the protection of pharmaceutical intellectual property rights has become the internal demand from China's pharmaceutical companies.

In recent years, China has made great progress in the IPR protection area of the biopharmaceutical industry. Law enforcement and related administrative agencies of the Chinese Government have carried out many joint initiatives to protect drug patents and to make advances in establishing the mosaic of rights needed to build and sustain an innovative biopharmaceutical sector. I believe, the international cooperation between China and US biopharmaceutical companies and the promotion of development of IPR protection for the medical products, would bring the unexpectable importance for both countries.

Since 2009, SINO-PhIRDA and PhRMA have successfully held two pharmaceutical industry summits and achieved positive results. I hope the summit this year can fully explore the ability of the two associations on bridging the pharmaceutical industries between China and U.S., facilitating the global pharmaceutical intellectual property protection and innovation development, making great contributions to promote people's healthcare level! I wish the summit a great success!

I sincerely wish the summit a great success. Thank you!

PR Protection
PROTECTION IPR

IPR PROTECTION IPR Protection PROTECTION IPR



中国医药工业科研开发促进会执行会长 宋瑞霖主持开幕式

Opening ceremony hosted by Song Ruilin, Executive President of SINO-PhIRDA

IPR PROTECTION
PROTECTION IPR



中国卫生部副部长陈啸宏致辞

Address by Chen Xiaohong, Vice Minister of China Ministry of Health



中国国家食品药品监督管理局副局长边振甲致辞

Address by Bian Zhenjia, Deputy Commissioner, SFDA

ino-U.S. Pharmaceutical Industry Summit 2011—

IPR PROTECTION IPR Protection PROTECTION IPR



中国国际贸易促进委员会、中国国际商会副会长张伟致辞 Address by Zhang Wei, Vice Chairman of CCPIT & CCOIC

PROTECTION PROTECTION PROTECTION | PROTECTIO



PhRMA高级副总裁罗德·亨特致辞

Address by Rod Hunter, Senior Vice President, PhRMA



美国商会国际知识产权中心执行副总裁 马克·埃利奥特致辞

Address by Mark Elliot, Executive Vice President, U.S. Chamber of Commerce -Global Intellectual Property Center

PROTECTION IPR

主题演讲 Presentatio



桑国卫副委员长发表题为《中国的新药研发与知识产权保护》的主题演讲。他说,中国政府高度重视知识产权保护。没有知识产权保护,就不可能有创新药物,特别是不可能有真正占领国际市场的创新药物。因此,强调中美生物医药企业的国际合作,以及促进改善医药产品的知识产权,对于中国、美国、欧洲,都具有不可估量的重要性。

Vice chairman Sang Guowei provides a presentation on "New Drug Development and IPR Protection in China". He says Chinese government pays high attention on the IPR issues. Drug innovation cannot be successful without intellecture protection, especially for the new drug which can occupy the global market. Therefore, emphasizing the international cooperation between China and US biopharmaceutical industry and promoting the improvement of pharmaceutical products intellectual property rights will have unexpectable impacts to China, US and the entire world.

PhRMA董事会主席克里斯·魏巴赫发表题为《中国引领 21世纪生命科学探索和发展的机会》主题演讲。他指出:创新是保障新药研发和临床应用的关键。中国对于全球生物医药行业的影响与日俱增,相信双方的合作将促进中美两国研制出更多安全而有效的药物,改善全世界患者的健康。

Mr. Christopher Viehbacher, PhRMA Chairman of Borad provides a presentation on "China leads the opportunities of life science exploration and development of 21st century". He points out that innovation is the key factor to ensure the new drug R&D and clinical practice. China is making increasingly impacts to the global biopharmaceutical industry, he believes the cooperation between PhRMA and SINO-PhIRDA will promote China and US to develop safer and more effective drugs and further improve the global health.



Sino-U.S. Pharmaceutical Industry Summit 2011—

1、18日上午演讲主题:医药知识产权法律制度

Topic 1: Pharmaceutical Intellectual Property Legal System



中国国际商会副秘书长林舜杰主持

Hosted by Lin Shunjie, Deputy Secretary-General, CCOIC



中国国家知识产权局医药生物发明审查部部长 张清奎作题为《中国医药知识产权法律制度》的主题报告

Speech by Zhang Qingkui, Director, Division of General Affair, The Pharmaceutical and Biological Invention Examination Department, SIPO



辉瑞公司高级副总裁、首席知识产权律师罗伊·沃尔德伦作题为《以平衡的政策鼓励二者并存:美国医药工业的创新和有竞争力的仿制药工业的形成》的主题报告

Speech by Roy Waldron, Senior Vice-President, Associate General Counsel, Chief Intellectual Property Counsel, Pfizer



IPR PROTECTION
PROTECTION IPR

中国国家食品药品监督管理局药品注册 司司长张伟作题为《药品注册与知识产权 保护》的主题报告。

Speech by Zhang Wei, General Director of Department of Drug egistration (Department of TCMs & Ethno-Medicines Supervision) of SFDA.

IPR PROTECTION PROTECTION IPR

PR PROTECTION PR Protection IPR

IPR PROTECTION

中国外商投资企业协会药品研制和开发行业委员会(RDPAC)总经理卓永清作题为《加强法规建设促进中国的药物创新》的主题报告Speech by Joseph Cho, Managing Director, RDPAC

IPR PROTECTION

IPR Protection

PROTECTION IPR



2、18日下午第一阶段演讲主题:医药知识产权保护与医药创新发展

Topic 2: Intellectual Property Rights Protection and Pharmaceutical Industry Innovation Development



中国药促会副会长、石药集团有限公司董事长蔡东晨主持

Hosted by Cai Dongchen, SINO-PhIRDA Vice President, Chairman of the Board of CSPC



中国最高人民法院知识产权庭法官罗霞作题为《医药产业发展与 知识产权保护》的主题报告

Speech by Judge Luo Xia, Supreme People's Court of P.R. China



赛诺菲安万特公司研发总监、美国国立卫生研究院前院长伊莱亚斯· 塞乌尼作题为《美国医药知识产权保护与医药创新》的主题报告

Speech by Dr. Elias Zerhouni, Head of Research and Development, Sanofi (former Director of the U.S. National Institutes of Health and Special Envoy to the President for Science & Technology)



中国贸促会专利商标事务所副所长龙传红作题为《有关专利链接的若干问题》的主题报告

Speech by Long Chuanhong, Vice President, CCPIT Patent and Trademark Law Office



默克公司亚太区研发副总裁张明强作题为《药品研发过程中面临的挑战》的主题报告

Ming-Qiang Zhang, Vice-President, Asia Pacific R&D, MSD





演讲嘉宾与参会者互动交流 Panel Discussion

PROTECTION

3、18日下午第二阶段演讲主题: 医药知识产权保护与社会公众健康权益

Topic 3 Pharmaceutical Intellectual Property Rights Protection and Public Health Rights



中国药促会理事、广西梧州中恒集团股份有限公司 董事长许淑清主持

Hosted by Xu Shuqing, Director of SINO-PhIRDA, and Chairman of the Board of Guangxi Wuzhou Zhongheng Group Co., Ltd



美国医药创新委员会联席主席、犹他州前州长、卫生与公众服务部前部长迈克尔·莱维特作题为《知识产权保护方面的合作》的主题报告

Speech by Michael Leavitt, Co-Chairman of the Council for American Medical Innovation (Former Governor of Utah and Former Secretary of the U.S. Department of Health and Human Services)



浙江贝达药业有限公司董事长丁列明作题为《医药知识产权保护与社会 公众健康权益》的主题报告

Speech by Ding Lieming, CEO of Zhejiang Beta Pharma

Protection & Prot

北京瑞恒信达知识产权代理事务所所长曹津燕作题为《权与责-药品专利保护与公共 利益的平衡》的主题报告

Speech by Cao Jinyan, Managing Partner, Leading Intellectual Property Firm



国际药品制造商协会联合会创新、知识产权和贸易事务总监安德鲁·詹纳作题为《行业视野下的创新、知识产权和全球公共卫生》的主题报告。

Speech by Andrew Jenner, Innovation, IP and Trade, International Federation of Pharmaceutical Manufacturers and Associations (IFPMA).

IPR Protection PROTECTION TPR





演讲嘉宾与参会者互动交流 Panel Discussion

IPR PROTECTION IPR Protection PROTECTION IPR



中国药促会理事、绿叶制药集团有限公司董事长刘殿波 对18日会议进行总结

Closing Remarks by Liu Dianbo, Director of SINO-PhIRDA, and Chairman of the board of LUYE Pharmaceutical Co., Ltd.







会场照片 Picture of the conference room

中国药促会副会长、扬子江药业集团有限公司董事长 徐镜人主持《联合声明》签署仪式

Hosted by Xu Jingren, SINO-PhIRDA Vice President, Chairman of the board of Yangtze River Pharmaceutical Group Co., Ltd

IPR Protection
PROTECTION IPR

PR PROTECTION
PROTECTION TO PR

PR PROTECTION
PROTECTION PROTECTION



中国药促会理事、上海信谊药厂有限公司总经理 顾浩亮介绍《联合声明》的主要内容

Joint Statement introduction by Gu Haoliang, Director of SINO-PhIRDA, and General Manager of Shanghai Sine Pharmaceutical Laboratories Co., Ltd



PhRMA高级副总裁罗德·亨特致辞 Brief address by Rod Hunter, Senior Vice President, PhRMA



中国药促会执行会长宋瑞霖与美国PhRMA高级副总裁罗德·亨特,分别代表中国药促会与美国PhRMA 共同签署了《联合声明》

SINO-PhIRDA Executive President Song Ruilin and PhRMA Senior Vice President Rod Hunter represents SINO-PhIRDA and PhRMA, respectively, sign on the Joint Statement.





— Sino-U.S. Pharmaceutical Industry Summit

1、第一阶段会议主题:医药知识产权发展战略

Topic 1: Development Strategies on Pharmaceutical Industry Intellectual Property Rights



中国药促会执行会长宋瑞霖主持第一阶段会议 Hosted by Song Ruilin, SINO-PhIRDA Executive President



中国药促会副会长、上海复星医药股份有限公司董事长陈启宇作题为《复星医药的知识产权战略》的报告

Speech by Chen Qiyu, SINO-PhIRDA Vice President and Chairman of the Board, Shanghai Fosun Pharmaceutical (Group) Co., Ltd



赛诺菲公司全球专利负责人罗伯特·德·伯纳丁作题为《演变的药物策略-知识产权及合作关系范例》的报告

Speech by Robert Deberardine, Global Head of Patents, Sanofi.



IPR PROTECTION

IPR Protection

PROTECTION IPR

石药集团高级研发总监牛占旗作题为 《知识产权与产品的生命周期管理策略》的报告

Speech by Niu Zhanqi, Senior Director of R&D, CSPC Pharmaceutical Group Co., Ltd





IPR Protection

礼来公司副总裁哈里森·库克作题为《新型化学企业的数据保护》的报告 Speech by Harrison Cook, Vice President, Eli Lilly o-U.S. Pharmaceutical Industry Summit 2011

Reprotection IPR

West and the second of the second second second second second

2、第二阶段会议主题:医药知识产权保护战略

Topic 2: Protection Strategies on Pharmaceutical Industry Intellectual Property Rights

IPR Protection
PROTECTION
PROTECTION TPR



美国PhRMA副总裁理查德·谢尔德高主持第二阶段会议 Hosted by Richard Kjeldgaard, PhRMA Deputy Vice President

IPR PROTECTION
IPR PROTECTION IPR



绿叶制药集团有限公司副总裁薛云丽作题为《创新型医药企业知识 产权战略运用》的报告

Speech by Xue Yunli, Vice President of Luye Pharmaceutical Co., Ltd



辉瑞公司高级副总裁、首席知识产权律师罗伊·沃尔德伦作题为《美国专利改革后对专利授权程序的选择》的报告

Speech by Roy Waldron, Senior Vice-President, Associate General Counsel, Chief Intellectual Property Counsel, Pfizer

19日上午中美医药企业关于医药知识产权战略圆桌对话会

Roundtable on Sino-U.S. Pharmaceutical Industry IPR Protection



中国药促会理事、南京圣和药业有限公司董事长王勇作题为 《中小企业知识产权保护和创新之路》的报告

Speech by Wang Yong, Director of SINO-PhIRDA and Chairman of the board of Nanjing Sanhome Pharmaceutical Co., Ltd



阿斯利康知识产权保护事务顾问沈建中作题为 《美国的损害赔偿法在专利纠纷中的运用》的报告

Speech by David Shen, legal counsel of IP rights in Asia, AstraZeneca







嘉宾互动Q&A

Sino-U.S. Pharmaceutical Industry Summit 2011 —

19日上午中美医药企业关于医药知识产权战略圆桌对话会 Roundtable on Sino-U.S. Pharmaceutical Industry IPR Protection













桑国卫副委员长与PhRMA董事会主席克里斯·魏巴赫就中美此次峰会的主题及中国药促会和美国PhRMA的长期合作交换意见

Vice Chairman Sang Guowei meets with PhRMA Chairman of the Borad Mr. Christopher Viehbacher and exchanges the opinions on the summit theme topic and the long-term cooperation between SINO-PhIRDA and PhRMA.

PROTECTION IPR

Sino-U.S.



桑国卫副委员长与美国PhRMA代表团部分成员亲切交谈 Vice Chairman Sang Guowei has a cordial talk with the PhRMA delegates.




3、会见期间的合影 Photograph





图为:桑国卫(中)、魏巴赫(左)、宋瑞霖(右)

Vice Chaiman Sang Guowei (Center), Mr. Christopher Viehbacher (Left), Mr. Song Ruilin (Right)



会见合影(从右到左依次为:卓永清、庄祥兴、罗德·亨特、桑国卫、 克里斯·魏巴赫、宋瑞霖、陈昌雄、王鑫)

Group Picture(From right:Joseph Cho,Chong Siong-Hin,Rod Hunter,Sang Guowei,Christopher Viehbacher,Song Ruilin,Chen Changxiong,Wang Xin)



图为:桑国卫(中)、魏巴赫(左)、 卫平(右)

Vice Chairman Sang Guowei (Center), Mr. Christopher Viehbacher (Left), Mr. Thomas Kelly (Right)

图为:宋瑞霖(左)、 亚当•南希(中)、 罗德•亨特(右)

Mr. Song Ruilin(Left) Ms. Nancy Adams(Center) Mr. Rod Hunter(Right)



Sino-U.S. Pharmaceutical Industry Summit 2011—



美国驻华使馆公使王晓岷致辞

Address by Robert S. Wang, Deputy Chief of Mission of the U.S. Embassy to China



中国商务部党组副书记、副部长姜增伟致辞

Address by Jiang Zengwei, Vice Minister and Member of the CPC Leadership Group of the Ministry of Commerce







桑国卫副委员长与美国驻华使馆公使王晓岷亲切交谈

Vice Charman Sang Guowei talks with Robert S. Wang, Deputy Chief of Mission of the U.S. Embassy to China



姜增伟副部长与魏巴赫主席亲切交谈 Vice Minister Jiang Zengwei talks with Mr. Christopher Viehbacher



中国药促会执行会长宋瑞霖与美国商会 国际知识产权中心执行副总裁 马克·埃利奥特亲切交谈

SINO-PhIRDA Executive President Song Ruilin talks with Mark Elliot, Executive Vice President, U.S. Chamber of Commerce - Global Intellectual Property Center

PR Protection
PROTECTION IPR





IPR PROTECTION IPF
IPR Protection IPF
IPR Protection IPF
PROTECTION IPR
PROTECTION IPR

中国药促会副会长、上海复星医药股份有限公司 董事长陈启宇主持晚宴

Hosted by Chen Qiyu, SINO-PhIRDA Vice President and Chairman of the Board, Shanghai Fosun Pharmaceutical (Group) Co., Ltd



Sino-U.S. Pharmaceutical Industry Summit 2011

IPR Protection PROTECTION TPR



美国副国务卿罗伯特•霍马茨致辞

Address by Robert Hormats, Under Secretary of United States.



中国工信部党组成员、总工程师朱宏任致辞

Address by Zhu Hongren, Chief Engineer and Member of CPC Leadership of China Ministry of Industry and Information Technology



中国国际商会秘书长赵晓笛致辞

Address by Zhao Xiaodi, Secretary-General of CCOIC



IPR PROTECT
IPR Protection
IPR PROTECTION IPI
IPR Protection
PROTECTION IPR
PROTECTION IPR

晚宴重要嘉宾合影(从左至右为:边振甲、克里斯·魏巴赫、 朱宏任、罗伯特·霍马茨、陈啸宏、宋瑞霖)

Photograph VIPs on Banquet Dinner (From Left: Bian Zhenjia, Christopher A. Viehbacher, Zhu Hongren, Robert D. Hormats, Chen Xiaohong, Song Ruilin).

陈啸宏副部长与魏巴赫、 霍马茨亲切交谈

Vice Minister Chen Xiaohong talks with Under Secretary Roberts Homarts and Mr. Christopher Viehbacher.

PR Protection
PROTECTION PROTECTION





边振甲副局长与魏巴赫主席亲切交谈

Mr. Bian Zhenjia, Deputy Commissioner of SFDA, talks with Mr. Christopher Viehbacher.



中国药促会执行会长宋瑞霖与外宾举杯祝贺峰会召开

SINO-PhIRDA Executive President Song Ruilin cheers with delegates to celebrate the summit success



宴会会场照片

Pictures of Banquet Dinner

IPR PROTECTION
PROTECTION IPR



PR Protection 宴会即将结束:PhRMA董事会主席克里斯·魏巴赫致答谢辞 PR Mr. Christopher Viehbacher, Chairman of Board of PhRMA, gives closing remarks for the banquet.

-U.S. Pharmaceutical Industry Summit 20

IPR Protection



桑国卫副委员长与陈啸宏副部长亲切交谈

Vice Chairman Sang Guowei talks with Mr. Chen Xiaohong, Vice Minister of MOH



桑国卫副委员长与边振甲副局长亲切交谈

Vice Chairman Sang Guowei talks with Mr. Bian Zhenjia, Deputy Commissioner of SFDA.



桑国卫副委员长、陈啸宏副部长与美国医药 创新委员会联席主席迈克尔·莱维特亲切交谈

Vice Chairman Sang Guowei and Vice Minister Chen Xiaohong talk with Mr. Michael Leavitt, Co-Chairman of the Council for American Medical Innovation.



桑国卫副委员长与魏巴赫主席亲切交谈 Vice Chairman Sang Guowei talks with

Vice Chairman Sang Guowei talks with Mr. Christopher Viehbacher during the conference.



陈啸宏副部长与迈克尔•莱维特亲切交谈 Vice Minister Chen Xiaohong talks with Mr. Michael Leavitt during the conference.

PROTECTION IPR






报到时的照片 Pictures of Registration





PROTECTION



19日早餐会后中美企业家合影 Group picture of CEO breakfast participants on 19th



会场外展板 Exhibition Boards



18日下午魏巴赫与中外媒体见面会 Mr. Viehbacher met with media on press conference on 18th afternoon.













Protection Protection TEC 忙碌的工作人员 Busy Registration



国内外媒体报道峰会

本次峰会受到广泛关注。30多家国内外媒体参会并进行报道。其中包括新华社、人民日报、彭博资讯、美联社、法新社、路透社等主流媒体也派记者参加了会议。各媒体客观翔实的报道显示:本次峰会取得了巨大成功,必将对中美医药交流产生重大而深远的影响。

This summit received widespread attention. Journalists from more than 30 domestic and international media attended the events, including the Xinhua News Agency, People's Daily, Bloomberg, Associated Press, Agence France Presse, Reuters and other mainstream medias. All reports showed that this summit achieved huge success and will make great positive influence on the exchange of Sino-U.S. pharmaceutical industries.















"2011中美医药产业峰会"情况简介

2011年10月18-19日,由中国国际商会、中国医药工业科研开发促进会(以下简称"中国药促会")、美国商会、美国药物研究与制造商协会(以下简称"美国PhRMA")共同主办的"2011中美医药产业峰会"在北京隆重举行。此次峰会的主题是"知识产权保护与医药产业的创新发展"。

出席峰会的中方领导有:全国人大常委会副委员长、国家"重大新药创制"科技重大专项技术总师、工程院院士桑国卫,卫生部副部长陈啸宏,中国商务部党组副书记、副部长姜增伟,工信部党组成员、总工程师朱宏任,国家食品药品监管局副局长边振甲,中国国际贸易促进委员会、中国国际商会副会长张伟等;出席峰会的外方领导和嘉宾有:美国药品研究与制造商协会董事会主席、欧洲制药工业协会联合会副主席、赛诺菲制药集团首席执行官克里斯•魏巴赫,美国医药创新委员会联席主席、美国前犹他州州长、前卫生与公众服务部部长迈克尔•莱维特先生,美国药品研究与制造商协会高级副总裁罗德•亨特,美国商会全球知识产权中心执行副主任马克•埃利奥特,赛诺菲制药集团全球研发部总裁、美国前国立卫生院院长伊莱亚斯•塞乌尼(曾和礼),美国副国务卿罗伯特•霍马茨(Robert D. Hormats)等。参加此次峰会的中外代表还有中国药促会会员单位高管、美国PhRMA成员企业高管组成的代表团以及中美两国医药产业界从事新药研发、企业管理和知识产权研究的学者和企业家代表共200余人。

在18日的峰会上,中美专家围绕"医药知识产权法律制度"、"医药知识产权保护与医药的创新发展"、"医药知识产权保护与社会公众健康权益"等议题做了多场主旨报告,并与参会代表展开了深入的互动讨论。19日上午,峰会还组织了议题为"医药知识产权发展和保护战略"的中美企业家圆桌会议,共同讨论知识产权保护与医药产品创新的相关问题。18日下午,中国药促会和美国PhRMA代表中美医药产业界共同签署了《关于加强知识产权保护、促进行业创新、发展及改善公共卫生的联合声明》。在18日中国国际商会和中国药促会共同举办的午餐会和招待晚宴上,美国驻华使馆公使、使团副团长王晓岷,美国副国务卿罗伯特·霍马茨分别致辞,表达了他们对此次峰会的肯定和祝贺,并对中美医药产业创新发展的长期合作充满期待。

峰会的成功召开与联合宣言的签署标志着中美医药产业界的交流和合作已经上升到一个崭新的高度,即将开创全新的历史局面,对中美医药产业界来说具有里程碑式的意义。中国药促会将以此次峰会为契机,以两协会的合作为平台,不断加强和推动中国生物医药创新企业与国际制药企业的技术对话与合作。

PROTECTION TPR

Brief Introduction

2011 Sino-U.S. Pharmaceutical Industry Summit was co-hosted by China Chamber of International Commerce (CCOIC), China Pharmaceutical Industry Research and Development Association (SINO-PhIRDA), US Chamber of Commerce, Pharmaceutical Research and Manufacturers of America (PhRMA) on October 18th -19th, 2011. Theme of this year is Intellectual Property Rights Protection & Pharmaceutical Industry Innovation and Development.

Chinese senior officials includes: Sang Guowei (Vice Chairman of the Standing Committee of National People's Congress, Chairman of the General Expert Committee of National Major Science and Technology Project "Innovation and Development of New Drugs", Academician of Chinese Academy of Engineering), Chen Xiaohong (Vice Minister of China Ministry of Health), Jiang Zengwei (Deputy Secretary of Party Leadership and Vice Minister of Commerce of PRC), Zhu Hongren (Chief Engineer and Member of Party Leadership of China Ministry of Industry and Information Technology), Bian Zhenjia (Deputy Commissioner of SFDA), Zhang Wei (Vice Chairman of CCPIT & CCOIC). VIPs from US delegation includes: Christopher Viehbacher (Chairman of Board of PhRMA, Vice Chairman of European Federation of Pharmaceutical Industries and Associations (EFPIA), CEO of Sanofi), Michael Leavitt (Co-Chairman of the Council for American Medical Innovation, Former Governor of Utah and Former Secretary of the U.S. Department of Health and Human Services), Rod Hunter (Senior Vice President of PhRMA), Mark Elliot (Executive Vice President, U.S. Chamber of Commerce - Global Intellectual Property Center), Elias Zerhouni (Head of Research and Development of Sanofi, former Director of the U.S. National Institutes of Health and Special Envoy to the President for Science & Technology), Robert Hormats (Under Secretary of State) and et al. More than 200 China and foreign guests participated in this summit, including senior officials from SINO-PhIRDA and PhRMA member companies, researchers in new drug innovation, business management and IPR areas.

During the summit on 18th, China and foreign experts provided excellent presentations around the issues on "Pharmaceutical Intellectual Property Legal System", "Intellectual Property Rights Protection and Pharmaceutical Industry Innovation Development" and "Pharmaceutical Intellectual Property Rights Protection and Public Health Rights", and had great interactive discussions. Roundtable on Sino-U.S. Pharmaceutical Industry IPR Protection was hold in the morning of 19th, which invited representatives from domestic and foreign entrepreneurs and discussed related issues on Intellecture Property Rights Protection and Pharmaceutical Product Innovation. In the afternoon of 18th, SINO-PhIRDA and PhRMA represented China and US pharmaceutical industry, respectively, signed the Joint Statement on Strengthening Intellectual Property Rights Protection, Promoting Industry Innovation and Development, and Improving Public Health. During the 18th meeting luncheon and banquet dinner co-hosted by CCOIC and SINO-PhIRDA, Robert S. Wang (Deputy Chief of Mission of the U.S. embassy to China) and Robert Hormats (Under Secretary of State), respectively, gave their remarks to the summit and expressed the congratulations, and fully expectation for the long-term cooperation between China and US pharmaceutical industry in the future.

The success of the summit with the Joint Statement signed by Sino-US pharmaceutical industry showed that the exchanges and cooperation have risen to a new level. It will open a new page in history, and will be a milestone between Sino-US pharmaceutical industries. SINO-PhIRDA will take the summit as a good opportunity, the cooperation of between two associations as the platform, continue to strengthen and promote the communication and cooperation on innovative technology between Chinese and international pharmaceutical companies.



"2011日 sino-u.s. U.S. Pharmaceutical Industry Summit 2011 1中美医药产业峰会"纪念册